Triple targeting host-guest drug delivery system based on lactose-modified azocalix[4]arene for tumor ablation
Host-guest drug delivery systems (HGDDSs) have been studied in an effort to modify the characteristics of therapeutic agents through noncovalent interactions, reduce toxic side effects and improve therapeutic effects. However, it is still an important task to continuously improve the targeting ability of HGDDSs, which is conducive to the development of precision medicine. Herein, we utilize the lactose-modified azocalix[4]arene (LacAC4A) as a triple targeting drug carrier customized for antitumor purposes. LacAC4A integrates three targeting features, passive targeting through the enhancing permeability and retention effect, active targeting by the interactions of lactose and the asialoglycoprotein receptors on the surface of tumor cells, and stimuli-responsive targeting via the reduction of the azo group under a hypoxia microenvironment. After loading doxorubicin (DOX) in LacAC4A, the supramolecular nanoformulation DOXLacAC4A clearly showed the effective suppression of tumor growth through in vivo experiments. LacAC4A can achieve effective targeting, rapid release, and improve drug bioavailability. This design principle will provide a new material for drug delivery systems.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Materials horizons - 10(2023), 5 vom: 09. Mai, Seite 1689-1696 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Juan-Juan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
80168379AG |
|---|
| Anmerkungen: |
Date Completed 20.02.2024 Date Revised 20.02.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1039/d3mh00018d |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353319953 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353319953 | ||
| 003 | DE-627 | ||
| 005 | 20240220232133.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1039/d3mh00018d |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1300.xml |
| 035 | |a (DE-627)NLM353319953 | ||
| 035 | |a (NLM)36825769 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Juan-Juan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Triple targeting host-guest drug delivery system based on lactose-modified azocalix[4]arene for tumor ablation |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.02.2024 | ||
| 500 | |a Date Revised 20.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Host-guest drug delivery systems (HGDDSs) have been studied in an effort to modify the characteristics of therapeutic agents through noncovalent interactions, reduce toxic side effects and improve therapeutic effects. However, it is still an important task to continuously improve the targeting ability of HGDDSs, which is conducive to the development of precision medicine. Herein, we utilize the lactose-modified azocalix[4]arene (LacAC4A) as a triple targeting drug carrier customized for antitumor purposes. LacAC4A integrates three targeting features, passive targeting through the enhancing permeability and retention effect, active targeting by the interactions of lactose and the asialoglycoprotein receptors on the surface of tumor cells, and stimuli-responsive targeting via the reduction of the azo group under a hypoxia microenvironment. After loading doxorubicin (DOX) in LacAC4A, the supramolecular nanoformulation DOXLacAC4A clearly showed the effective suppression of tumor growth through in vivo experiments. LacAC4A can achieve effective targeting, rapid release, and improve drug bioavailability. This design principle will provide a new material for drug delivery systems | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Doxorubicin |2 NLM | |
| 650 | 7 | |a 80168379AG |2 NLM | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 650 | 7 | |a Lactose |2 NLM | |
| 650 | 7 | |a J2B2A4N98G |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Rong, Rui-Xue |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Zong-Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Bing |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Ying-Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Hua-Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Xin-Yue |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Ke-Rang |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Dong-Sheng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Materials horizons |d 2014 |g 10(2023), 5 vom: 09. Mai, Seite 1689-1696 |w (DE-627)NLM235528501 |x 2051-6355 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2023 |g number:5 |g day:09 |g month:05 |g pages:1689-1696 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1039/d3mh00018d |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2023 |e 5 |b 09 |c 05 |h 1689-1696 | ||